Altimmune Inc. is making progress on its Covid-19 vaccine more than four months after jumping into that arena.
The Gaithersburg biopharma said Monday it has emerged from preclinical trials with positive results, positioning the clinical-stage company to start manufacturing the candidate, called AdCovid, in the third quarter of this year and start a phase 1 clinical trial in the fourth quarter.
Image: Dr. Vipin Garg is president and CEO of Altimmune. COURTESY ALTIMMUNE